<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 309 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page308.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=309">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 309 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 309</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=309"><img src="../thumb/309.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>272 / 2020-04                                                            Anti-Microbials - 18.12
   tunist. infects./other HIV assoc.complicat. may contin., risk of sex.  made aware of dangers of hypersens./to contact dr.immed.& carry   C max/AUC/C min., lopinavir + ritonavir incr. tenofovir AUC/C min., indinavir
   contact transmiss.not reduc., elderly.  incl.alert card with them at all times, monit.ser.lipids & bld.gluc.,   incr.tenofovir C max, tenofovir incr. C max of abacavir/indinavir, tenofovir
   Drug interactions: Incr./prolong.therapeut.& advers. effs.of drugs   pts.with known risk facts.for liv.dis., susp.treatm.upon clin./ lab.  incr. C max/AUC/Cmin of atazanavir, poss. incr. metformin/dofetilide/
   metabol.by CYP3A, lopinavir therapeut. eff.reduc.by meds.that in-  findings suggest.lact.acidos./hepatotox., poss. mitochondr.dysfunct.  pilsicainide plasma conc. with dolutegravir., poss.decr.dolutegravir
   duc.CYP3A, plasma conc.of zidovudine & abacavir potent. reduc.,   aft.in utero foet.expos.to nucleos./nucleot.analogues., pancreatit.to   conc. with oxcarbazepine/ phenytoin/phenobarb./ carbamazepine/
   tenofovir conc.incr., efavirenz & nevirapine decr. plasma conc.of   be consid. in pts.develop.abdom.pain/naus./vomit./ elevat. biochem.  St John’s Wort though no studies, reduc. dolutegravir plasma conc.
   other protease inhibit., delavirdine incr.lopinavir plasma conc.,   markers & discont.ther.unt. pancreatit. diagnos.excl., eval.any inflam.  with etravine/ efavirenz/ nevirapine/rifampicin, incr.dolutegravir
   conc.of indinavir/ nelfinavir/saquinavir & amprenavir poss. incr.,   sympts. without delay & init.treatm.as necess., pts.to report joint   plasma conc.with atazanavir/telaprevir/atazanavir + ritonavir, decr.
   fosamprenavir low.amprenavir & lopinavir conc., tipranavir reduc.  ache/pain/stiffn.or diffic.in movem.as osteonecros.poss., hepatit.B   dolutegravir conc.with tipranavir + ritonavir/ fosamprenavir + ritona-
   lopinavir AUC/cmin, lopinavir. conc.decr.by nelfinavir/dexametha-  co-infect., opportunist. infects.& other HIV complicat.may still devel.,   vir/darunavir + ritonavir /darunavir + ritonavir + etravirine
   sone /phenobarb./ phenytoin & carbamazepine, antiarrhythm. ami-  advis.pt.that antiretrovir.ther.will not prev. transmiss.& appropr.pre-
   odarone/bepridil/ system. lidocaine & quinidine conc.incr., digox.lev.  caut.to contin., lamivudine excret.in human milk, init.ther.by physic.  LANOGRAV, (Sonke) Ranbaxy [P/S]
   incr., warfar. conc. poss.affect., trazodone conc.incr., bupropion lev.   exper.in HIV-infect. managem., admin.separate preps. where dos.  Dolutegravir sod.equiv to dolutegravir 50 mg, lamivudine 300 mg,
   decr., atovaquone therapeut.conc. decr., fluticasone propion.plasma   adjustm.indicat., not recom.where creatinine clear.less than 50 ml/  tenofovir disoproxil fumarate 300 mg
   conc.incr., felodipine/ nifedipine & nicardipine ser.conc.incr., disulfi-  min., human carcinogen. potent.unknown, mild myocard. degenerat.   Indications: Treatm.of HIV infect.adults ≥ 18 yrs.
   ram-like reacts.poss.with disulfiram & metronidazole as sol.contains   in mice/rats, elderly., minimise all modifiab. coron.heart dis.risk facts.  (S4) TABS, 52/20.2.8/0718
   alcoh., incr.potent. for ser.adverse reacts.with HMG-CoA reduct. in-  incl.hypertens. /hyperlipidaem./ diabet.mellit./smok.  3000572-001, 30, R234,60
   hibit.metabol.by CYP3A4 pathway, incr.conc.of cyclospor./ tracrolim.   Drug interactions: Abacavir AUC incr.by ethanol, syst.methadone   Dosage: Consult.prod.info.of each therapeut. compon. of regim.bef.
   & sirolim., ketoconazole & itraconazole ser.conc.incr., voriconazole   clear.incr., trimethoprim incr. lamivudine plasma lev.  init.treatm., init.ther.by physic. exper.in HIV infect.managem. Adults:
   steady-state AUC decr., clarithromycin/rifabutin AUC incr., metha-  1 tab. once dly. Rifampicin decr.bld.lev.of dolutegravir & supplement.
   done plasma conc.low., ethinyl estradiol lev.decr., rifampin signific.  KOVATRAX, (Activo) Macleods [P/S]  dos.of dolutegravir poss.reqd.
   decr.conc., sildenafil/ tadalafil & varadenafil conc.incr., St John’s   Dolutegravir sod.equiv to dolutegravir 50 mg, lamivudine 300 mg,   Contraindications: Ren.funct.impairm. (creatin. clear. &lt; 80 ml/
   Wort reduc. plasma conc.result.in loss of therapeut. eff.& resist. to   tenofovir disoproxil fumarate 300 mg   min), pregn.& lactat., women of child-bear. age not using highly ef-
   active ingred.or therapeut. class of protease inhibit.  Indications: Treatm.of HIV infect.adults ≥ 18 yrs.  fect.contracept., concom. adefovir dipivoxil/dofetilide/pilsicainide
                                                              / didanosine/ metformin, pts.&lt; 18 yrs., mod.to sev. hepat.impairm.
                                (S4) TABS, 52/20.2.8/0772.770
   KAVIMUN PAED, Mylan [P/S]    3000605-001: 30, R493,00      Side effects: Freq: Hyperlactataem., headache, insomn, cough,
   Abacavir                     Dosage: Consult.prod.info.of each therapeut. compon. of regim.bef.  nas.sympts., pneum., N&V, upper abdom. pain, diarrh., rash, alo-
   Indications: Antiretroviral combinat.ther.for HIV treatm.in in-  init.treatm., init.ther.by physic. exper.in HIV infect.managem. Adults:   pec., prurit., myalg., arthralg., musc.disord., fatig., malaise, asthen.,
   fect. childr.                1 tab. once dly. Rifampicin decr.bld.lev.of dolutegravir & supplement.  pain, back/chest pain, fev., dizzin., depress., anx., anorex., dyspeps.,
   (S4) TABS, 46/20.2.8/0006    dos.of dolutegravir poss.reqd.  flatul., abnorm.dreams, periph. neuropathy., proxim.tubulopathy,
   718160-001: 60 mg, 60, R303,51  Contraindications: Uncontrolled ren.fail., pregn. & lactat., women   proteinur., incr. creatin., ac.tubul.necros., nephrogen.diabet. in-
   Dosage: For use by physic.exper.in HIV managem. Crush/mix tabs.   of child-bear.age not using highly effect.contracept., concom.ade-  sipid., hypophosphataem., dyspn., abdom. discomf., ren.insuffic.,
   with small amount food/water & ingest immed. Childr.3 mnths-12   fovir dipivoxil/ dofetilide/pilsicainide/didanosine/ metformin, pts.&lt;   ren.fail., sweat. Less freq: Angioed., hepat.steatos., hypokalaem.,
   yrs: Recomm.dos: 8 mg/kg 2xdly up to max.600 mg dly. 3-5,9kg:   18 yrs., mod.to sev. hepat. impairm.  suicid. ideat./ attempt., neutropen., anaem., thrombocytopen.,
   1 tab.morn. & even. 6-9,9 kg: 1,5 tab. morn. & even. 10-13,9 kg:   Side effects: Freq: Hyperlactataem., headache, insomn, cough,   lact.acidos./sev.hepatomegaly with steatos.incl fatal.cases esp.
   2 tabs morn.& even. 14-19,9 kg: 2,5 tab. morn.& even. 20-24,9 kg:   nas.sympts., pneum., N&V, upper abdom. pain, diarrh., rash, alo-  women, sev.ac. exacerbat. of hepatit.B aft.discont, lipodystrophy,
   3 tabs. morn.& even.         pec., prurit., myalg., arthralg., musc.disord., fatig., malaise, asthen.,   late onset neurologic.disord.in childr.expos.in utero, pancreatit.,
   Contra-indications: Safety & effic.in signif. underly.liv.disords.  pain, back/chest pain, fev., dizzin., depress., anx., anorex., dyspeps.,   incr.AST/ALT, rhabdomyolys., decr. bone miner.dens., osteopen.,
   not est., sev. hepat.impairm., safety in pregn. not est., lactat.,   flatul., abnorm.dreams, periph. neuropathy., proxim.tubulopathy,   fract., allerg. react., hepatit., incr.amylase, myopathy, osteomalac.,
   childr.und.3 mnths.          proteinur., incr. creatin., ac.tubul.necros., nephrogen.diabet. in-  hypersens., immune reconstitut. syndr. Freq.unknown: Pure red
   Side-effects: Fatal hypersens.reacts.indicat.of multi-organ/body   sipid., hypophosphataem., dyspn., abdom. discomf., ren.insuffic.,   cell aplas., Fanconi syndr., autoimmun.disords., incr.weigh., oste-
   syst.involvem., lipodystrophy, pancreatit., rash, GI disturbs., dyspn.,   ren.fail., sweat. Less freq: Angioed., hepat.steatos., hypokalaem.,   onecros., incr.bld lipids/gluc.
   cough, fev., lethargy , malaise, mouth ulc., sore throat, adult resp.   suicid. ideat./ attempt., neutropen., anaem., thrombocytopen.,   Warnings and special precautions: Not indic. for treatm.of
   distress. syndr., resp./hepat./ren.fail., oed., lymphadenopathy, hypo-  lact.acidos./sev.hepatomegaly with steatos.incl fatal.cases esp.  chron.hepatit.B infect., safety & effic. not est.in HBV & HIV co-
   tens., conjunctivit., anaphylax., headache, paraesthes., lymphopen.,   women, sev.ac. exacerbat. of hepatit.B aft.discont, lipodystrophy,   infects., monit.hepat. funct. for sev.mnths. in pts.co-infect.with
   elev.LFT, myalg., myolys., arthralg., hyperlactataem., lact.acidos.,   late onset neurologic.disord.in childr.expos.in utero, pancreatit.,   HIV & HBV who discont.ther.& appropr.init.of anti-hepatit. B ther.
   erythema multiforme, Stev.-Johns.syndr., tox.epiderm. necrolysis,   incr.AST/ALT, rhabdomyolys., decr. bone miner.dens., osteopen.,   poss.necess., metabol.abnormalit., eval. for signs of fat redistribut.,
   fatig., osteonecros.         fract., allerg. react., hepatit., incr.amylase, myopathy, osteomalac.,   monit.fast. ser. lipids & bld.gluc.levs., CV risk assessm.with evid.
   Special precautions: Screen.for HLA-B*5701 allele in all pts. bef.  hypersens., immune reconstitut. syndr. Freq.unknown: Pure red   of lipodystrophy, pts.to seek med.advice if exper. joint pain/aches/
   init.ther./re-init.in pts. prev. toler. ther., not to be init. in pts.known   cell aplas., Fanconi syndr., autoimmun.disords., incr.weight., oste-  stiffn./movem.diffic.as osteonecros. poss., opportunist.infects.&
   to carry HLA-B*5701 allele unless no other option avail., discont.  onecros., incr.bld lipids/gluc.  other HIV complicat. may still devel., ARV ther.will not prev. risk
   treatm. in case of hypersens.react.& not to be re-challeng., lact.aci-  Warnings and special precautions: Not indic. for treatm.of   of transmiss.through sex.cont.& bld.contamin. & appropr.precaut.
   dos./sev.hepatomegaly with steatos.incl. fatalit.with ther.alone/in   chron.hepatit.B infect., safety & effic. not est.in HBV & HIV co-in-  to contin., discont.in clinic./lab. find. suggest.lact.acidos./hepato-
   combin., obese women, hepatit./other known liv. dis.risk fact. incl.  fects., monit.hepat. funct. for sev.mnths.in pts.co-infect.with HIV   tox., pts.with known risk for liv.dis, pts.with hepatomegaly/ hep-
   cert.meds.& alcoh., interrupt ther.in case of clinic./lab.find.of lact.  & HBV who discont.ther.& appropr.init.of anti-hepatit. B ther.poss.  atit/ other risk facts.for liv.dis./hepat.steatos., pts. co-infect.with
   acidos./ hepatomegaly, hepatit.C co-infect./pts.treat.with alpha in-  necess., metabol.abnormalit., eval. for signs of fat redistribut.,   hepatit.C & treat.with alpha interferon & ribavarin, eff.on clinic.
   terferon & ribavirin, meas.fast.ser.lipids/ bld.gluc., lipid disord.man-  monit.fast.ser. lipids & bld.gluc.levs., CV risk assessm.with evid.   progress.of HIV-1 not demonst., investig.childr.expos.in utero to
   agem., poss.high virolog. fail./ resist.at early stage when abacavir   of lipodystrophy, immune reconstit.inflam.syndr., pts. to seek med.  nucleoside & nucleotide analog.for poss. mitochondr. dysfunct.
   & lamuvidine were combin.with tenofovir disoprox. fumarate as   advice if exper.joint pain/aches/ stiffn./movem.diffic.as osteone-  in case of relev.S&S, discont. ther. until pancreatit.excl.in cases
   once dly.regim., reproduct.toxic.in animals, mitochondr.dysfunct.,   cros.poss., opportunist. infects.& other HIV complicat.may still de-  of N&V/abdom. pain/ elev.biochem.mark., ren.funct.impairm.,
   eval./treat inflamm. sympt. when necess., pts.to alert phys.in case   vel., risk of transmiss.through sex.cont.& bld. contamin.not prev.&   safety & effic.not est.in signific.underly. liv. disords., monit.liv.funct.
   of joint pains/stiffn./movem.diffic., ther.not a cure, opportunist. in-  appropr.precaut.to contin., discont.in clinic./lab.find. suggest.lact.  with pre-exist.liv.dysfunct., cons. ther.interrupt./discont.if evid.of
   fects. & other HIV complicat.may still devel., poss.inflamm.react.to   acidos./ hepatotox., known/other risk fact.for liv.dis, hepatomegaly/   worsen. liv. dis., monit.ren.funct.bef.init.ther & periodic. thereaft.
   asymptom./ resid. opportunist. infect.in pts.with sev.immune defic.   hepatit/hepat.steatos., co-infect. with hepatit.C & treat.with alpha   (4 wkly dur.1  yr.of treatm. & 3 mnthly theraft.), avoid combin.with
                                                                   st
   when init.ther., not proven to prev.transmiss. through sex.cont./bld.  interferon & ribavarin, eff.on clinic.progress.of HIV-1 not demonst.,   concurr./recent nephrotox. meds., concom.meds.secret.by same
   contamin., appropr.precaut. to contin., poss. MI risk, chron.hepatit.   investig.childr.expos.in utero to nucleoside & nucleotide analog.for   ren. pathway, avoid in antiretrov.exper.pts.with HIV-1 harbour.K65R
   B or C, discont. ther. in case of worsen.liv.dis.  poss. mitochondr. dysfunct.in case of relev.S&S, discont. ther. until   mutat., bone monit. with patholog. bone fract.hist./osteopen.risk,
   Drug interactions: Poss. ecr.conc.with potent enzymat. induc.  pancreatit.excl.in cases of N&V/abdom. pain/ elev.biochem.mark.,   Ca & vit.D supplement. poss.benefic., incr.risk for sev./fat. hepat.
   eg. rifampicin/phenobarb./ phenytoin, incr.AUC with ethanol, syst.  adverse effs.in chron.hepatit.B or C co-infect., ref.to PI of concom.
   methadone clear.incr., poss.interact.with retinoid cmpds.but not stud.  ren.funct.impairm., safety & effic.not est.in signific.underly. liv. dis-  hepat.B or C meds., immune reconstit.inflam.syndr., exacerb.of
                                ords., monit.liv.funct.with pre-exist.liv.dysfunct., cons. ther.inter-
   KIVEXA, GSK [P/S]            rupt./discont.if evid.of worsen.liv. dis., monit.ren.funct.bef.init.ther   hepatit. dur/ aft.treatm., limit.data in elderly &gt; 65 yrs., discont.
                                              st
   Abacavir sulph. 600 mg, lamivudine 300 mg.  & periodic. thereaft. (4 wkly dur.1  yr.of treatm.& 3 mnthly theraft.),   ther.immed.if any hypersens.react.susp./ occurs.& init.appropr.ther.,
   Indications: Treatm.of HIV infect.adults & adolesc. from 12   avoid combin.with concurr./recent nephrotox. meds., concom.meds.  avoid in wom.plan. pregn., reproduct.toxic.report., init.pregn.test
   yrs of age                   secret.by same ren. pathway, avoid in antiretrov.exper.pts.with   in women of childbear.potent./periodic.dur.treatm.& when pregn.
   (S4) TABS, A39/20.2.8/0030   HIV-1 harbour.K65R mutat., bone monit. with patholog. bone fract.  suspect., lamivudine excret. in breast milk, monit.with concom.co-
   707321-001: 30, R828,48      hist./osteopen.risk, Ca & vit.D supplement. poss.benefic., incr.risk   trimoxazole, concom. tacrolimus as ren funct poss.affect., concom.
   Dosage: Stabil.pts.on indiv.meds.bef.switch. Do not admin.to pts.  for sev./fat. hepat. adverse effs.in chron.hepatit.B or C co-infect.,   ETR not recomm.unless receiv.concom.ATV + RTV/ LPV + RTV or
   weigh.less than 40 kg as it’s a fix. dos.tab.  ref.to PI of concom.hepat.B or C meds., exacerb. of hepatit.dur/aft.  DRV + RTV, do not admin.concom.with emtricitabine/other cytidine
   Adults & adolesc over 12 yrs: 1 tab.once dly.  treatm., liv.flares esp. in decompensat.liv.dis., limit.data in elderly &gt;   analogues., avoid chron. co-admin.of sorbitol/other osmot.act.po-
   Contraindications: Mod & sev.hepat.impairm., concom.zalcit-  65 yrs., discont. ther.immed.if any hypersens.react. susp./ occurs.&   ly-or monosaccharide acohols, admin.2 hrs.bef./6 hrs. aft. polyval.
   abine/emtricitabine not recomm., safety in pregn. not est., breast   init.appropr.ther., avoid in wom. plan. pregn., reproduct.toxic.report.,   cation-cont.antacids, admin.2 hrs.bef./ 6 hrs. aft.Ca/Fe supplem.
   feed.not recomm., childr.&lt;12 yrs  init.pregn.test in women of childbear.potent./periodic.dur.treatm.   Interactions: Isoniazid conc.poss incr.by dolutergravir, lamivu-
   Side effects: Fatal hypersens.reacts.pres.usually within 6 wks.of   & when pregn.suspect., lamivudine/tenofov. excret. in breast milk,   dine poss.inhib. intracellul. phosphorylat. of zalcitabine/cladrib-
   init.ther.(median 11 days) like a resp. dis./flu-like illn./gastro-enterit.  monit.with concom.co-trimoxazole, concom.tacrolimus as ren funct   ine, trimethoprim incr.lamivudine plasma lev., interacts. poss.with
   or reacts.to other meds., lact.acidos./sev.hepatomegaly with stea-  poss. affect., concom.ETR not recomm.unless receiv. concom.ATV +   hepatit.C antivir.meds., lamivudine incr. expos.& peak.plasma lev.
   tos, redistribut./accumulat.of body fat, elev. ser.lipid & bld.gluc.lev.,   RTV/ LPV + RTV or DRV + RTV, do not admin.concom.with emtricit-  of zidovudine, conc.of tenofovir/concom.med incr. with concom.
   osteonecros., hypersens. sympts worsen. with cont.ther., hypersens.  abine/other cytidine analogues., admin.2 hrs.bef./6 hrs.aft. polyval.   drugs elim.by glomerul.& act.tubul. secret., tenofov.ser.conc.incr.by
   reacts. are more sev.on re-challeng.incl.life-threaten. hypotens.&   cation-cont.antacids, admin.2 hrs.bef./ 6 hrs. aft.Ca/Fe supplem,   agents decr.ren. funct., C max & AUC of didanosine incr., atazanavir
   death within hrs., GI disturbs., fev., lethargy, skin rash, bld.dyscras.,   contains mannit.which may have laxat.eff.  incr. tenofovir C max/AUC/C min., lopinavir + ritonavir/ darunavir + ri-
   hyperlactaem., CNS effs., pancreatit., trans.rise in liv.enzymes, alo-  Interactions: Isoniazid conc.poss incr.by dolutergravir, lamivudine   tonavir incr.tenofovir AUC/C min., indinavir incr.tenofovir C max, teno-
   pec., erythema multiforme, Stev.-John.syndr. tox. epiderm. necrolys.,   poss.inhib.intracellul. phosphorylat. of zalcitabine/cladribine, tri-  fovir incr. C max of abacavir/indinavir, tenofovir incr. C max/AUC/Cmin
   arthralg., musc.disords, rhabdomyolys., fatig., malaise, MI, anorex.  methoprim incr.lamivudine plasma lev., interacts. poss.with hepatit.C   of atazanavir, sorbitol decr.lamivudine C max & AUC, poss. incr.met-
   Warnings and special precautions: Hypersens. reacts.to   antivir.meds., lamivudine incr. expos.& peak.plasma lev.of zidovu-  formin/dofetilide/pilsicainide plasma conc. with dolutegravir., poss.
   abacavir charact.by multi-organ/body syst. involvem.have proven   dine, conc.of tenofovir/concom.med incr. with concom.drugs elim.  decr.dolutegravir conc. with oxcarbazepine/ phenytoin/phenobarb./
   fatal, perman.discont. ther.if hypersens.react.occurs/suspect., do   by glomerul.& act.tubul. secret., tenofov.ser.conc.incr.by agents decr.  carbamazepine/ St John’s Wort though no studies, reduc. dolute-
   not re-challeng. pts.who have develop.hypersens.reacts., pts.to be   ren. funct., C max & AUC of didanosine incr., atazanavir incr. tenofovir   gravir plasma conc.with etravine/ efavirenz/ nevirapine/rifampicin,</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page308.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page304.html">304</a>&nbsp;&nbsp;&nbsp;<a href="page305.html">305</a>&nbsp;&nbsp;&nbsp;<a href="page306.html">306</a>&nbsp;&nbsp;&nbsp;<a href="page307.html">307</a>&nbsp;&nbsp;&nbsp;<a href="page308.html">308</a>&nbsp;&nbsp;&nbsp;<a href="page309.html">309</a>&nbsp;&nbsp;&nbsp;<a href="page310.html">310</a>&nbsp;&nbsp;&nbsp;<a href="page311.html">311</a>&nbsp;&nbsp;&nbsp;<a href="page312.html">312</a>&nbsp;&nbsp;&nbsp;<a href="page313.html">313</a>&nbsp;&nbsp;&nbsp;<a href="page314.html">314</a>
             </td>
             <td width="35%"><a href="page310.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page310.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
